拨康视云-B（02592.HK）7月7日收盘跌0.17%

证券之星消息，截至2025年7月7日收盘，拨康视云-B(02592.HK)报收于5.85港元，下跌0.17%，成交量274.4万股，成交额1569.8万港元。

资金流向数据方面，7月7日拨康视云-B无主力资金净流入，无超大单资金净流入，无大单资金净流入，中单资金净流出170.31万港元，小单资金净流出89.72万港元。

投行对该股关注度不高，90天内无投行对其给出评级。

Cloudbreak Pharma Inc. is a clinical-stage ophthalmology biotechnology company dedicated to the development of various treatments. The Company is focusing on the in-house discovery, development and commercialization of ophthalmic therapies. The Company has two Core Products, CBT-001 and CBT-009, both of which are being proprietarily developed. Its Core Product, CBT-001, is indicated for the treatment of pterygium (a benign proliferative ocular surface disease), and it has commenced a Phase III multi-regional clinical trial (MRCT) in the United States and China. Its Core Product, CBT-009, is indicated for the treatment of juvenile myopia (myopia in children and adolescents aged 5 to 19) and has completed Phase I/II clinical trials. Its other drug candidates are in a relatively early development stage, including two other clinical-stage drug candidates, which are CBT-006 and CBT-004, and four pre-clinical-stage drug candidates, which are CBT-007, CBT-199, CBT-145, and CBT-011.

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。